<DOC>
	<DOCNO>NCT02814123</DOCNO>
	<brief_summary>The closed-loop delivery system compose insulin pump , continuous glucose sensor dose algorithm calculates insulin dose infuse base sensor reading . Pramlintide drug analog amylin , hormone co-secreted insulin healthy individual , deficient people type 1 diabetes . Co-injection pramlintide insulin meal time improve glucose control type 1 diabetes . The purpose study compare effectiveness 2 strategy control day-and-night glucose level : 1 ) insulin-plus-placebo closed-loop delivery 2 ) insulin-plus-pramlintide closed-loop delivery . The hypothesis basal-bolus infusion insulin-plus-pramlintide closed-loop system improve blood glucose control compare insulin-plus-placebo infusion .</brief_summary>
	<brief_title>Effect Basal-Bolus Closed-Loop Co-Administration Insulin Pramlintide Improving Glycemic Control Type 1 Diabetes</brief_title>
	<detailed_description>The closed-loop delivery system compose insulin pump , continuous glucose sensor dose algorithm calculates insulin dose infuse base sensor reading . Pramlintide drug analog amylin , hormone co-secreted insulin healthy individual , deficient people type 1 diabetes . Co-injection pramlintide insulin meal time improve glucose control type 1 diabetes . The aim study assess efficacy simultaneous , closed-loop , basal-bolus infusion pramlintide insulin fix ratio ( i.e. , mimic co-formulation ) control glucose level compare insulin-plus-placebo closed-loop infusion . The investigator aim conduct double-blinded , randomize , crossover trial compare efficacy insulin-plus-placebo closed-loop delivery insulin-plus-pramlintide closed-loop delivery regulate glucose level period 24 hour study adult inpatient setting . At minimum ten day prior closed-loop intervention , pramlintide placebo initiate ( basal bolus ) use second pump . The hypothesis basal-bolus infusion insulin-plus-pramlintide closed-loop system improve blood glucose control compare insulin-plus-placebo infusion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Males female ≥ 18 year age . Clinical diagnosis type 1 diabetes least 12 month . ( The diagnosis type 1 diabetes base investigator 's judgment ; C peptide level antibody determination need . ) The subject insulin pump therapy least 6 month . HbA1c ≤ 10 % . Current ≤ 1 month use antihyperglycemic agent ( SGLT2 , GLP1 , Metformin , Acarbose , etc.… ) . Severe hypoglycemic episode within one month screening . Severe diabetes ketoacidosis episode within one month screening . Planned ongoing pregnancy . Known suspect allergy study drug . Gastroparesis . Use prokinetic drug stimulate gastric emptying ( domperidone , cisapride , metoclopramide ) . Clinically significant nephropathy , neuropathy retinopathy judge investigator . Recent ( &lt; 6 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . Current use glucocorticoid medication . Other serious medical illness likely interfere study participation ability complete trial judgment investigator . Failure comply team 's recommendation ( e.g . willing eat meals/snacks , willing change pump parameter , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Pramlintide</keyword>
	<keyword>Artificial Pancreas</keyword>
	<keyword>Closed-Loop System</keyword>
	<keyword>Insulin</keyword>
</DOC>